CSLLY News and Press, CSL Ltd ADR From 02/23/24

Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe Positive CHMP opinion is based on pivotal Phase 3 PROTECT Study results European Commission dec...

2024-02-23 07:05:14 ET More on Travere Therapeutics Travere Therapeutics, Inc. (TVTX) Q4 2023 Earnings Call Transcript Travere Therapeutics: Restructuring Away From Disaster Travere Therapeutics Q4 2023 Earnings Preview Travere inks licensing deal for sparsen...

2024-02-13 15:00:58 ET Summary CSL Limited achieved a +3% earnings beat for 1H FY 2024, and the company's full-year FY 2024 financial guidance was left unchanged. But CSL Limited's CSL112 trial results were unfavorable, which suggests that there might be an absence of meaningful p...

2024-02-13 00:53:08 ET CSL Ltd (CSLLY) Q2 2024 Earnings Conference Call February 12, 2024, 19:00 ET Company Participants Mark Dehring - Head, IR Paul McKenzie - MD, CEO & Executive Director William Mezzanotte - EVP & Head, Research and Development Her...

Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³ Canada NewsWire Strong CSL Behring portfolio growth especially Ig FINANCIAL HIGHLIGHTS 4 Revenue $8.05 billion , up 11% at CC 3 NPAT $1.90 billion 1 ...

2024-02-12 13:53:40 ET More on CSL CSL Limited: Positive Capital Return And Earnings Growth Expectations Arcturus, CSL win approval for world’s first self-amplifying mRNA vaccine in Japan Historical earnings data for CSL Dividend scorecard for CSL ...

CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human]) PR Newswire KING OF PRUSSIA, Pa. , Feb. 11, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today ...

2024-02-10 17:35:58 ET Major earnings expected after the bell on Monday include: Waste Management ( WM ) Arista Networks ( ANET ) Federal Realty Investment Trust ( FRT ) Star Bulk Carriers Corp. ( SBLK ) Cadence Design Systems ( CDNS ) Read ...

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster PR Newswire Study conducted by Meiji Seika Pharma in Japan Short communication follows previou...

2024-01-31 17:20:05 ET Summary Arcturus Therapeutics Holdings Inc. interim results from the phase 1b study, using ARCT-032 for the treatment of patients with Cystic Fibrosis, are expected in the 1st half of 2024. The global Cystic Fibrosis market is projected to grow to $12.9 bill...